Financial Daily from THE HINDU group of publications
Friday, Dec 16, 2005


News
Features
Stocks
Shipping
Archives
Google

Group Sites

Corporate - Announcements


Aurobindo Pharma gets USFDA nod to sell depression drug

Our Bureau

Hyderabad , Dec. 15

AUROBINDO Pharma Ltd has announced that it has received final approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Mirtazapine orally disintegrating tablets (ODT) in 15 mg and 30 mg dosages and tentative approval for 45 mg tablet form.

Mirtazapine ODT is the generic version of Organon's Remeron SolTab and is indicated for the treatment of major depressive disorder. The annual sales of Mirtazapine ODT in the US market are estimated at around $100 million.

In a press release here on Wednesday, the company said it would now be able to sell Mirtazapine orally disintegrating tablets in 15 mg and 30 mg dosages immediately and 45 mg dosage after the expiry of 180 days exclusivity period, which expires in February 2006.

According to the company, many generic players, in spite of having approval for Mirtazapine tablets, find it difficult to develop Mirtazapine orally disintegrating tablets. The company claims that it is one among very few companies that has shown its R&D capability by developing this complicated product.

Further, the company said with this USFDA approval for Mirtazapine ODT, its product portfolio for the US market has widened further and it expects to have significant share in the premium market.

More Stories on : Announcements

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
Celebrity Fashions IPO price band fixed at Rs 160-180


IOC saves Rs 1,500 cr with Kandla-Bhatinda crude pipeline
ONGC board to consider interim dividend
Natco launches anti-fungal drug
Aurobindo Pharma gets USFDA nod to sell depression drug
Yellow Pages to be distributed at select petrol bunks in Coimbatore
Kirloskars cannot hike stake in Toyota Kirloskar beyond 11% — Original share buyback deal renegotiated
MoU controversy: DPE panel to study versions of ONGC, Ministry?
Nagarjuna Construction prices GDR at $ 5.11
IDMA patent awards for Aurobindo Pharma
VSP bags energy award
Learning to manage `tomorrow'
Managing with more
Finding the leader
Tata Steel to buy Thai co for $130 m
US co to buy stake in Biocon's subsidiary
Japanese firm Yanmar forays into farm implements market
Volkswagen team likely to visit Mangalore today
Glenmark inks pact with InvaGen for US market
IOC-OIL combine explores tie-up with Norway co
Torrent Pharma announces stock split, 1:1 bonus
Fresh revival plan for Dunlop to be submitted to BIFR on Jan 27
Hindustan Latex targets Rs 1,000-cr turnover
Venky's bets big on export of value-added chicken to Japan
Mankind Pharma targets Rs 1,000-cr turnover in 5 years
HPL eyes 20% sales growth
ISMT to focus on exports


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line